Business Context and Reporting Period
This Form 8-K is a Current Report filed by NAYA Biosciences, Inc. (NAYA) on January 16, 2025, covering events occurring between January 10 and January 14, 2025. The filing details the consummation of a public offering, the entry into material definitive agreements, and a notice regarding Nasdaq listing compliance.
Key Financial Metrics and Capital Structure
- Capital Raised: Gross proceeds of approximately $9.5 million from the sale of 13,615,171 Units at $0.70 per Unit.
- Debt Repayment: The Offering triggered mandatory repayments totaling approximately $911,000, including $500,000 toward a Senior Secured Convertible Debenture, $129,800 on a convertible promissory note, and $281,156 on other convertible notes.
- Preferred Stock Redemption: Agreed to redeem 4,000 shares of Series C-2 Preferred Stock for $4,000,000, with accrued dividends of $104,444.44 remaining outstanding.
- Transaction Costs: Placement agent fees of 6.5% (or 5.0% for certain investors) of gross proceeds, plus reimbursement of expenses up to $90,000.
Material Changes and Use of Proceeds
The Company utilized the net proceeds from the Offering for specific strategic and operational purposes:
- Up to $2,500,000 for the second installment of the purchase price for the Wisconsin Fertility Institute.
- $4,000,000 to redeem Series C-2 Preferred Stock.
- Up to $1,950,000 to satisfy outstanding debt obligations.
- The remaining balance allocated to clinical trials, product development, marketing, management team strengthening, and working capital.
Outlook, Risks, and Contingencies
Nasdaq Listing Compliance
On January 10, 2025, NAYA received notice from Nasdaq for failing to hold an Annual Meeting of Shareholders (ASM) within the required timeframe. The Company has 45 days (until February 24, 2025) to submit a compliance plan. If accepted, an extension of up to 180 days (until June 30, 2025) may be granted. Failure to regain compliance could result in delisting.
Proposed Corporate Actions
The Company intends to hold an ASM in March 2025 to approve:
- Election of directors and ratification of auditors.
- Amendment to increase authorized common stock to at least 100,000,000 shares.
- A reverse stock split with a ratio between 1-for-2 and 1-for-20.
- Issuance of common stock upon conversion of Series C-1 and C-2 Preferred Stock.
Lock-Up Provisions
The Company is restricted from issuing new common stock or equivalents for 90 days and from engaging in Variable Rate Transactions for 12 months following the Offering closing.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 6.5% placement fee and $90,000 expense reimbursement.
- Confirm the specific reverse stock split ratio approved at the March 2025 Annual Meeting.
- Monitor the status of the Nasdaq compliance plan submission by February 24, 2025, and the subsequent acceptance decision.
- Review the full text of the Securities Purchase Agreement and Redemption Agreement filed as Exhibits 10.1 and 10.2 for detailed covenants.
- Track the utilization of funds specifically allocated to the Wisconsin Fertility Institute acquisition.